The Oncology Institute of Hope and Innovation

What The Oncology Institute of Hope and Innovation does

The Oncology Institute of Hope and Innovation (NASDAQ: TOI) is a community oncology practice founded in 2007 and headquartered in Downey, California, that delivers medical oncology, hematology, radiation oncology, and ancillary cancer services across more than 100 clinic locations in five states (California, Nevada, Arizona, Oregon, and Florida). The company employs approximately 501–1,000 staff, including 180+ clinicians, and serves a patient population of roughly 1.9 million. Its clinical model is organized around value-based and risk-bearing payer arrangements, including participation in the CMS Enhancing Oncology Model (EOM), where it generated $1.8M in Period 3 savings at more than $6,400 per episode.

The company's product surface combines direct patient care with an integrated in-house specialty pharmacy dispensary, clinical trials infrastructure operated through Helios Research, and specialty Centers of Excellence (e.g., Lung Cancer, Cancer Center for Women). Technology is delivered through partnerships rather than proprietary platforms: Tempus for genomic profiling, McKesson/US Oncology Network for drug distribution and practice operations, Ascertain for AI-driven administrative workflow automation, and Trial Library for AI-enabled clinical trial matching. The business model is reimbursement-driven — fee-for-service medical oncology revenue plus value-based shared-savings contracts and specialty pharmacy capture — with public-company disclosure since the November 2021 SPAC merger with DFP Healthcare Acquisitions Corp at an approximately $334M raise and $842M initial valuation.

Recent operating results include Q1 2026 revenue of $147.44M (+41.2% YoY), Q4 2025 revenue of $141.96M (the first profitable quarter on adjusted EBITDA), and FY2025 revenue of $502.73M, against a trailing twelve-month net loss of approximately $0.54/share. The company is publicly traded on NASDAQ under the ticker TOI, with a market capitalization of approximately $350M as of April 2026 and a 104% implied upside to a $7.00 analyst price target. Material recent events include a $16.5M private placement led by Deerfield in March 2025, the appointment of Kim Tzoumakas to the board in February 2026 (adding pharmacy expertise), and a November 2025 cybersecurity incident at vendor TriZetto affecting approximately 3.4 million individuals.

Name

The Oncology Institute of Hope and Innovation

Legal name

The Oncology Institute of Hope and Innovation

Website

https://theoncologyinstitute.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The Oncology Institute of Hope and Innovation is a community oncology practice operating 100+ clinics across five U.S. states (CA, NV, AZ, OR, FL), serving approximately 1.9 million patients with medical, radiation, and hematology oncology plus in-house specialty pharmacy, value-based payer contracts, and clinical trials.

Ownership category

akta.pro rank

Product category

Community Oncology Services

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK)

Keywords

• Community oncology care
• Value-based cancer care
• Precision oncology services
• Hematology and infusion therapy
• Oncology clinical trials

Headquarters

HQ city

Downey

HQ country

United States

HQ region

North America

Offices14 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Value-Based Care / Capitation Contracts: The company generates revenue through value-based care arrangements, including capitation contracts with Medicare and commercial payers. Revenue is earned through delivering oncology care to attributed patient populations under risk-sharing arrangements. The company reported growth in capitation contracts in Q4 2025.
2. In-House Pharmacy Services: The company operates an in-house dispensary providing prescriptions to patients with courier service to clinics. The pharmacy segment has been rapidly expanding under new management, contributing to accelerated topline growth.
3. Fee-for-Service / Treatment Delivery: Revenue from chemotherapy, immunotherapy, radiation therapy, and other cancer treatments billed to payers. The company offers comprehensive cancer care services including infusions, radiation, and clinical trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

The Oncology Institute operates a multi-site community oncology practice delivering the full spectrum of cancer care services — chemotherapy, radiation therapy, immunotherapy, precision targeted therapy, hormone therapy, blood transfusions, clinical trials (via Helios Research), and supportive counseling — across 100+ clinic locations in five states. Care is coordinated through the High-Value Cancer Care (HVCC) Program with 24/7 symptom management, supported by an in-house dispensary, in-house lab testing, and financial counseling, and reimbursed under value-based capitation contracts with Medicare and commercial payers.

Product overview

The Oncology Institute operates as a multi-site community oncology practice offering a unified platform of cancer care services. The core offering includes chemotherapy, radiation therapy, immunotherapy, precision targeted therapy, hormone therapy, blood transfusions, and clinical trials, all supported by the High-Value Cancer Care (HVCC) Program for care coordination. The organization provides specialized centers including a Cancer Center for Women and Lung Cancer Center of Excellence, along with in-house dispensary, lab testing, and financial counseling services. With over 100 clinics across five states and approximately 1.9 million patients served, the practice focuses on delivering evidence-based, value-based oncology care in community settings close to patients' homes.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemotherapy Cancer treatment using powerful medications administered orally or intravenously to systematically target and destroy cancer cells throughout the body. Offered to cancer patients across TOI's 100+ clinic locations.
• Radiation Therapy High-precision radiation treatment using X-rays, gamma rays, and charged particles to shrink tumors and kill cancer cells, offered as both external beam and internal radiation therapy for cancer patients.
• Immunotherapy Therapy that boosts the body's immune system to recognize and attack cancer cells while limiting damage to healthy cells, including monoclonal antibodies, CAR-T cell therapy, and checkpoint inhibitors.
• Precision Targeted Therapy Cancer treatment using specialized drugs that identify and attack specific proteins and molecules in cancer cells to stop disease growth and spreading while minimizing harm to healthy cells.
• Hormone Therapy Treatment that limits or blocks the body's naturally occurring hormones to slow or stop the growth of hormone-sensitive cancers such as breast and prostate cancer.
• Blood Transfusions Outpatient blood transfusions providing red blood cells, platelets, plasma, and hemoglobin transfusions to support cancer patients during treatment.
• Compassionate Counseling Supportive services including mental health counseling, nutrition counseling, smoking cessation programs, survivorship planning, and end-of-life counseling for cancer patients.
• Clinical Trials Access to promising new cancer treatments through clinical trials via the Helios Research partnership, covering Phase 1-4 trials across solid tumors, hematological malignancies, benign hematology, supportive care, and diagnostic studies, with screening and identification by Helios in partnership with TOI providers.
• High-Value Cancer Care (HVCC) Program Care coordination program providing proactive care navigation, 24/7 symptom management with health coach access, and a mobile-based care platform that supports cancer patients across medical, emotional, social, and psychological needs.
• In-House Dispensary On-site pharmacy services with courier delivery to clinics, specialty pharmacy relationships, and financial assistance programs for co-pay and medication support for cancer patients.
• Cancer Center for Women Specialized women's cancer care providing breast and gynecologic cancer treatment, including cervical and ovarian cancers, through dedicated clinics.
• Lung Cancer Center of Excellence Specialized lung cancer center offering advanced diagnostic tools, precision medicine, and comprehensive treatment options for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), led by Dr. Edgardo S. Santos Castillero in Fort Lauderdale.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• TempuscoreStrategic or Co-development Partner · 11 March 2026Genomic profiling partnership where Tempus conducted a study with TOI demonstrating how advanced comprehensive genomic profiling features identify actionable findings for cancer patients. The research found that 12% of patients across pilot and expanded cohorts had potentially actionable findings identified solely through advanced Tempus features such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing.
• Trial LibrarycoreStrategic or Co-development Partner · 3 December 2025AI-enabled platform expanding access to clinical trials as a care option. TOI is part of Trial Library's network of 320+ clinics and 1,500+ providers nationwide. The partnership aims to integrate clinical research into standard care delivery and expand patient access to clinical trials.
• AscertainflagshipTechnology or Integration · 13 November 2025Co-development of 'near-touchless' AI-driven administrative workflows for outpatient oncology visits. Initial AI system deployment has significantly reduced authorization submission times and is expected to save up to $2 million in operational costs in 2026.
• Helios ResearchcoreStrategic or Co-development PartnerClinical research partnership offering patients access to promising new therapies through clinical trials. The partnership provides Phase 1-4 clinical trial conduct across various solid tumors, hematological malignancies, benign hematology, supportive care and diagnostic test studies. Helios handles trial screening and identification of potentially eligible patients in partnership with TOI clinic medical providers.
• US Oncology NetworkminorStrategic or Co-development PartnerTOI is associated with the US Oncology Network which supports community oncology providers with technology, administrative services, and resources. The network includes 129 imaging centers across 18 states and is mentioned in the context of how McKesson supports community oncology practices.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• OneOncology: OneOncology is a network of community oncology practices similar to TOI's model, providing value-based cancer care across multiple states. Both organizations compete for the same patient populations, payer contracts, and clinical talent in community oncology settings.
• 21st Century Oncology: 21st Century Oncology is one of the largest integrated oncology networks in the U.S., offering radiation oncology and cancer care across multiple states. It was previously led by Kim Tzoumakas (now on TOI's board), and represents a scaled community oncology competitor with similar geographic and service line breadth.
• Virginia Cancer Specialists: Virginia Cancer Specialists is part of the TOI-affiliated network and provides comprehensive community-based oncology care including precision oncology and clinical trials. It represents a similar regional oncology practice model with comparable service offerings and patient populations.
• American Oncology Network: American Oncology Network is a rapidly growing alliance of community oncology practices providing value-based cancer care, similar to TOI's model. Both organizations compete for payer contracts, physician recruitment, and geographic expansion opportunities in community oncology.
• Florida Cancer Specialists & Research Institute: Florida Cancer Specialists is a large community oncology practice operating across Florida with clinical trial programs through Sarah Cannon. It directly competes with TOI in Florida and represents a regional peer with similar scale and service offerings.

Broad incumbents

• US Oncology Network (McKesson): The US Oncology Network supports 1,000+ community oncology providers across 18 states with technology, administrative services, and resources through McKesson. TOI is actually affiliated with this network, making it both partner and primary competitive reference point for scale and capabilities.
• City of Hope: City of Hope acquired Cancer Treatment Centers of America (CTCA) to expand community oncology reach. It represents a larger, well-capitalized academic-community hybrid oncology provider competing for complex cancer patients and clinical trial enrollment.
• Tenet Healthcare (USPI): Tenet Healthcare operates USPI ambulatory surgery centers and broader healthcare services including oncology-adjacent offerings. As a large diversified healthcare operator, it represents competitive pressure and partnership opportunities in community oncology expansion.

Others

• Flatiron Health: Flatiron Health (a Roche subsidiary) provides oncology-specific electronic health records and real-world evidence platforms to community oncology practices, including technology infrastructure that TOI relies on. It is an enabling technology partner/competitor rather than direct care provider.
• Tempus AI: Tempus is TOI's strategic partner for advanced genomic profiling and is also a publicly traded precision medicine company. While not a direct care provider, Tempus represents both a partnership and competitive reference point for precision oncology capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/OncologySupport
• Facebookfacebook.com/oncologyinstitute
• LinkedInlinkedin.com/company/oncologyinstitute

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Oncology Institute of Hope and Innovation